Pharmacoeconomics of Empirical Antifungal Use in Febrile Neutropenic Hematological Malignancy and Hematopoietic Stem Cell Transplant Patients

Stuart J Turner; Sharon CA Chen; Monica A Slavin; David CM Kong


Expert Rev Pharmacoeconomics Outcomes Res. 2013;13(2):227-235. 

In This Article

Five-year View

It is anticipated that newer antifungal agents will continue to become available, including the newest azoles and echinocandins and monoclonal antibody-based therapies.[57] An increased interest in combination therapy is likely to occur owing to perceived, but not proven, better drug efficacy and to prevent antifungal resistance.[58–60] These developments further highlight the need for pharmacoeconomic analyses to determine the relative merits of the alternatives available, and with respect to the focus of this review, the cost–effectiveness of these alternatives in empiric antifungal therapy. Finally, as diagnostic tests evolve to allow for increased predictive power, pre-emptive therapy may become a more popular treatment strategy compared with a prophylactic strategy. This will result in fewer patients exposed to unnecessary antifungal therapy.